Company Updates covers news from Brilliant Blue Biosciences. Research & Industry News highlights relevant developments published by external sources, summarised and attributed to them.
The latest installment in BioPharma Dive's data visualization series features a look at the emerging popularity of RNAi developers, and the funding that came with it.
Source: BioPharma Dive
Read more →Application of the high-precision technique is part of a clinical trial to treat a genetic disease that can cause liver and nerve damage.
Source: Nature
Read more →ALTER is a programmable RNA base editor built entirely from human proteins. By using human AGO2 instead of bacterial CRISPR–Cas proteins, ALTER mitigates a key risk factor for harmful immune responses in therapeutic applications while also proving generally more effective than dCas13-based editors.
Source: Nature Biotechnology
Read more →Huntington's disease is caused by repetitive "stutters" in DNA—specifically repeated CAG sequences—that expand abnormally over time, leading to toxic protein accumulation that contributes to the progression of the disease. There is currently no cure for this rare and fatal genetic disease.
Source: Medical Xpress
Read more →Human Argonaute is repurposed for RNA editing.
Source: Nature Biotechnology
Read more →Gene editing is moving from lab bench to approved therapies. But how should sponsors measure editing efficiency without unnecessary complexity?
Source: Labiotech.eu
Read more →Gene therapy is no longer the future of medicine—it's reality. Treatments that replace, silence or edit genes are already changing clinical care.
Source: Medical Xpress
Read more →Scientists have long been interested in cellular nanodiscs, tiny particles made from natural cell membranes that mimic many of the functions of living cells. While previous studies demonstrated the therapeutic potential of nanodiscs for drug delivery, detoxification and vaccines, one fundamental question remained unanswered: How does size influence how well they work?
Source: Phys.org
Read more →Peter Mac scientists have developed a way to precisely target the "unique molecular fingerprint" created when two genes become abnormally fused together, a discovery that could lead to a new way to treat a wide array of cancers.
Source: Medical Xpress
Read more →A new engineered gene-editing system, proven in bacteria and showing promise for use in plants, animals and humans, addresses some limitations of current gene-editing tools, with the goal of improving their use in research, crop development and disease treatment.
Source: Phys.org
Read more →Dillico’s GMP-ready Continuous Manufacturing by Engineering, Not Hype
Source: GEN — Genetic Engineering & Biotechnology News
Read more →Researchers develop light-responsive silica nanoparticles that release antibacterial drugs on demand, offering a potential way to improve chronic wound treatment.
Source: Nanowerk
Read more →We co-develop nanocarrier and biosensing programmes with pharma, biotech and academic groups — from target selection through scale-up.
